Hugel announced on Jan. 16 that it recently acquired product approval for its botulinum toxin Letybo (Botulax) in Lithuania, Bulgaria, Iceland, and Croatia.
Earlier, after receiving a product approval opinion from the Heads of Medicines Agencies (HMA) in January 2022, Hugel successfully launched in the European market, starting with its first shipments to France and Austria in March, becoming the first Korean botulinum toxin company to enter the European local market.
With this approval, Hugel has completed its expansion into 30 European countries, including the big five markets of Germany, the U.K., France, Italy, and Spain.
Europe, along with China and the United States, is one of the world’s top three botulinum toxin markets. The region has seen the rapid spread of awareness and interest in medical cosmetic procedures, with a diversification in the age of consumers undergoing treatments and an increase in male consumers.
A Hugel representative said, “As the product leading the domestic botulinum toxin market for seven consecutive years, we will continue to enhance our influence in the European market based on our superior quality and efficacy.”